---
title: "Hubei Guangji Pharmaceutical Co.,Ltd. (000952.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000952.SZ.md"
symbol: "000952.SZ"
name: "Hubei Guangji Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-03-03T10:26:52.870Z"
locales:
  - [en](https://longbridge.com/en/quote/000952.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000952.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000952.SZ.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/000952.SZ.md) | [繁體中文](https://longbridge.com/zh-HK/quote/000952.SZ.md)


# Hubei Guangji Pharmaceutical Co.,Ltd. (000952.SZ)

## Company Overview

Hubei Guangji Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical raw materials, pharmaceutical preparations, and feed additives in China and internationally. It also exports its products. The company was founded in 1969 and is based in Wuxue, China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.guangjipharm.com](https://www.guangjipharm.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-03T04:30:10.000Z

**Overall: D (0.75)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 214 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -10.57% |  |
| Net Profit YoY | -0.93% |  |
| P/B Ratio | 2.75 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2662271429.23 |  |
| Revenue | 608071496.60 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -21.62% | E |
| Profit Margin | -38.62% | E |
| Gross Margin | 29.52% | C |
| Revenue YoY | -10.57% | D |
| Net Profit YoY | -0.93% | C |
| Total Assets YoY | -17.01% | E |
| Net Assets YoY | -20.83% | E |
| Cash Flow Margin | -258.90% | D |
| OCF YoY | -10.57% | D |
| Turnover | 0.21 | D |
| Gearing Ratio | 62.67% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hubei Guangji Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-10.57%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-0.93%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.75",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2662271429.23",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "608071496.60",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-21.62%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-38.62%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "29.52%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-10.57%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-0.93%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-17.01%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-20.83%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-258.90%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-10.57%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.21",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "62.67%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -11.34 | 170/222 | - | - | - |
| PB | 2.75 | 124/222 | 2.75 | 2.32 | 1.97 |
| PS (TTM) | 4.38 | 115/222 | 4.39 | 3.75 | 3.33 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | B | B | A |
| 02 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 03 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 04 | Salubris (002294.SZ) | B | B | C | A | B | B |
| 05 | Haisco (002653.SZ) | B | C | B | C | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/000952.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/000952.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/000952.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/000952.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**